Related Experiment Video
Updated: Feb 25, 2026
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker
Kunio Iura1,2, Kenichi Kohashi1, Takeaki Ishii1,2
1Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan.
Abstract:
Cancer-testis (CT) antigens have promise as targets for immunotherapy, because of their restricted expression in tumor or testis tissue. MAGEA4 is both a MAGE family member and a CT antigen, and has attracted attention as a potential immunotherapeutic target. We investigated MAGEA4 expression by immunohistochemistry in bone and soft tissue tumor specimens that consisted of 35 malignant or intermediate and 24 benign histological subtypes, in order to evaluate its possible utility as an immunotherapy target and its potential use as a diagnostic marker when combined with another CT antigen, NY-ESO-1. Among these tumors, MAGEA4 was detected in 82.2% of synovial sarcomas, 67.7% of myxoid liposarcomas, 43.8% of osteosarcomas, 41.4% of angiosarcomas, 24.6% of malignant peripheral nerve sheath tumors (MPNSTs), and 21.4% of chondrosarcomas. NY-ESO-1 expression was found in 88.2% of myxoid liposarcomas, 61.1% of synovial sarcomas, 31.3% of osteosarcomas, 21.4% of pleomorphic liposarcomas, 16.7% of desmoplastic small round cell tumors, and 14.3% of chondrosarcomas. Benign tumors and non-tumorous tissue, except for testis tissue, did not express MAGEA4 or NY-ESO-1. Combined use of MAGEA4 and NY-ESO-1 increased the sensitivity, specificity, positive predictive values, and negative predictive values for distinguishing synovial sarcoma from spindle cell tumors and other mimicking tumors, compared to individual use of MAGEA4 or NY-ESO-1. Our results support the immunotherapy targeting MAGEA4 or NY-ESO-1 can be an ancillary therapy in the above-mentioned tumors, and the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma combined with NY-ESO-1.
Insights
Cancer-testis antigens like MAGEA4 show promise for immunotherapy. MAGEA4 and NY-ESO-1 can help diagnose synovial sarcoma and other tumors, aiding in targeted cancer treatments.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Diagnostics
Background:
- Cancer-testis (CT) antigens are promising immunotherapy targets due to restricted expression in tumor and testis tissues.
- MAGEA4 is a CT antigen of interest for immunotherapeutic applications.
- NY-ESO-1 is another CT antigen with potential therapeutic and diagnostic value.
Purpose of the Study:
- To investigate MAGEA4 expression in bone and soft tissue tumors.
- To evaluate MAGEA4's utility as an immunotherapy target and diagnostic marker, especially when combined with NY-ESO-1.
- To assess the diagnostic performance of MAGEA4 and NY-ESO-1 in distinguishing synovial sarcoma from other tumors.
Main Methods:
- Immunohistochemistry was used to detect MAGEA4 and NY-ESO-1 expression.
- Bone and soft tissue tumor specimens, including malignant, intermediate, and benign subtypes, were analyzed.
- Diagnostic performance metrics (sensitivity, specificity, PPV, NPV) were calculated for individual and combined marker use.
Main Results:
- MAGEA4 was detected in various sarcomas, including 82.2% of synovial sarcomas and 67.7% of myxoid liposarcomas.
- NY-ESO-1 expression was high in myxoid liposarcomas (88.2%) and synovial sarcomas (61.1%).
- Combined MAGEA4 and NY-ESO-1 significantly improved diagnostic accuracy for synovial sarcoma compared to individual markers. Benign tumors showed no expression.
Conclusions:
- MAGEA4 and NY-ESO-1 are expressed in specific bone and soft tissue tumors, supporting their potential as immunotherapy targets.
- The combined use of MAGEA4 and NY-ESO-1 enhances diagnostic specificity and sensitivity for synovial sarcoma.
- These CT antigens hold potential as ancillary diagnostic markers and therapeutic targets in relevant tumor types.
More Related Videos
09:31Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024